Pulmonary Drugs Market - Industrial Outlook, Company Shares, Analysis, Growth, Forecast to 2022
Global
Pulmonary
Drugs Market is expected to grow at a significant CAGR in the
upcoming years as the scope and its applications are rising enormously across
the globe. Pulmonary drugs are the drugs used to treat chronic obstructive
pulmonary disease. It helps to reduce shortness of breath, prevent
exacerbations, and control coughing and wheezing. Some of the pulmonary drugs
are used with devices called nebulizers or inhalers.
The
factors that are playing a major role in the growth of Pulmonary Drugs Market
are rising number of patients with chronic respiratory diseases and growing
number of smokers around the world. In addition, increasing investments for
research and development to produce effective drugs is another factor driving
overall market. On the other hand, the strict regulatory process for drug
approval and availability of counterfeit drugs will slow down and hinder the
growth of the overall market.
Pulmonary
Drugs Market is segmented based on drug class, distribution channel,
application, and region. Drug class such as Combination Drugs, Inhaled
Corticosteroids (ICS), Anticholinergics, Long-Acting Beta2-Agonists (LABA),
Short-Acting Beta2-Agonists (SABA), Antihistamines, Vasodilators, and others
(Antieukotrienes, MAbs, Antileukotrienes, Antibiotics, and others) classify the
market.
Distribution
Channel such as E-Commerce, Hospital Pharmacies, Drug Stores, Retail
Pharmacies, and others classify Pulmonary Drugs Market. Application into Cystic
Fibrosis, Asthma & COPD, Pulmonary Arterial Hypertension, Allergic
Rhinitis, and others classify Pulmonary Drugs Market. Pulmonary Drugs Market is
segmented geographically Americas (North America, Latin America), Europe
(Eastern Europe, Western Europe), Asia Pacific, Latin America, Middle East and
Africa. Globally, North America accounts for the largest market share of the
industry and is estimated to lead the overall market in the upcoming years.
Europe and Asia Pacific follow suit. On the other hand, Asia Pacific is
estimated to grow at fastest pace in the upcoming years. The reason being, high
medical demands.
The
key players of Pulmonary Drugs Market are Sunovion Pharmaceuticals Inc.,
AstraZeneca plc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Teva
Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Actelion
Pharmaceuticals, Inc. These players are concentrating on inorganic growth to
sustain themselves amongst fierce competition. As such, mergers, acquisitions,
and joint ventures are the need of the hour.
Market Segment:
Geographically, this report is segmented
into several key Regions, with production, consumption, revenue (million USD),
market share and growth rate of Pulmonary Drugs in these regions, from 2012 to
2022 (forecast), covering
•
North America
•
Europe
•
China
•
Japan
•
Southeast Asia
•
India
Global Pulmonary Drugs market
competition by top manufacturers, with production, price, revenue (value) and
market share for each manufacturer; the top players including
•
AstraZeneca plc
•
Bayer AG
•
Teva Pharmaceutical Industries Ltd.
•
Actelion Pharmaceuticals, Inc.
•
Boehringer Ingelheim GmbH
•
F. Hoffmann-La Roche Ltd.
•
Merck & Co., Inc.
•
Novartis AG
•
GlaxoSmithKline plc
•
Sunovion Pharmaceuticals, Inc.
Request Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/pulmonary-drugs-market/request-sample
Comments
Post a Comment